Urothelial Cancers
BLADDER CANCER
Bladder cancer is the second most common urologic malignancy, with close to 70,000 new cases and 14,000 deaths reported each year. Eighty percent of cases occur in patients older than age 50 with the median age at diagnosis of 70 years. Males are affected more commonly than females in a 3:1 ratio. Urothelial carcinoma (UC) accounts for 90% of these cases; squamous cell carcinoma (SCC) accounts for about 5%; and adenocarcinoma accounts for 2%. Whites are more commonly affected than blacks by a 4:1 ratio. What follows pertains to urothelial cancers, except where indicated.
Etiology
As with most cancers, no cause of bladder cancer is known. However, there is strong circumstantial evidence that environmental exposure to carcinogens plays a major role. Up to 33% of cases may be related to occupational exposures to carcinogenic aromatic amines in dye, textile, rubber, cable, printing, and plastics industries. Four proven bladder carcinogens are (a) 3-naphthylamine, (b) 4-aminobiphenyl (xenylamine), (c) 4-nitrobiphenyl, and (d) 4,4-diaminobiphenyl (benzidine). Significant nonoccupational exposures are cigarette smoking, dietary nitrosamines, Schistosoma haematobium of the bladder, cyclophosphamide chemotherapy, and therapeutic radiation of the prostate or cervix. A latency period of 15 to 30 years from first exposure to carcinogens to diagnosis of a tumor is common.
Pathology
Urothelial cancer is described as a field defect because the entire urothelium, from the renal pelvis to the bladder, is bathed in the urinary carcinogens. However, most tumors occur on the floor of the bladder where exposure is greatest. These tumors usually grow in a papillary fashion and are often multicentric. Angiolymphatic invasion is a poor prognostic sign.
Urothelial cancers are now categorized into non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).
NMIBC (80%) include the following:
Papillary urothelial neoplasia of low-malignant potential (PUNLMP)
Low-grade papillary carcinoma (Ta)
High-grade papillary carcinoma (Ta)
Carcinoma in situ (CIS) – always high grade (Tis)
High-grade tumor invading subepithelial connective tissue only (T1)
MIBCs (20%) are all high-grade tumors (T2 and above). Urothelial dysplasia has abnormal cytologic and nuclear characteristics that are preneoplastic but are insufficient to be classified as CIS. CIS appears as a flat, non-papillary erythematous lesion confined to the urothelial mucosa. Its reddish appearance can be mistaken for inflammatory changes or radiation cystitis. CIS is histologically characterized by severe urothelial dysplasia, is clearly more aggressive, and is associated with a poorer prognosis than papillary lesions. CIS has a high recurrence rate of >80%; most are multifocal; and progression occurs in 50% to 75%. CIS is a precursor lesion for invasive cancer. Tumors labeled PUNLMP are generally considered benign but do have a risk of recurrence. They demonstrate minimal cytologic atypia and are not associated with invasion (<4%) or metastases, but can recur in 35% of cases. True papillary carcinoma of the bladder is now classified as only low grade or high grade. Eighty percent of high-grade papillary carcinomas will invade if left untreated.
Staging Nomenclature and Criteria
Normal histologic anatomy of the bladder includes the inner urothelium, the lamina propria, and the outer muscularis propria. Smooth muscle fibers found in the lamina propria, referred to as the muscularis mucosa, must not be confused with the true muscularis propria which constitutes the detrusor muscle. A muscularis mucosa is difficult to identify. Cancer invasion of the muscularis mucosa can be misinterpreted. Uncertainty can arise particularly in the transurethral resection (TUR) specimens. Urothelial cancer staging requires good communication between the urologist and pathologist. The TNM classification is reviewed in the following table.
▪ TNM Staging Classification | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Tumor Grade
Tumor grade refers to the histologic morphology as determined by cellular atypia, nuclear abnormalities, and the number as well as location of mitotic figures. UC is only classified as low grade or high grade.
Low grade—60% recur while only 10% invade
High grade—invasion and progression in 50%
Workup
▪ History
Gross hematuria is the hallmark of bladder cancer either alone or associated with irritative symptoms (frequency, urgency, and dysuria). Twenty percent of patients with gross hematuria will have
a urologic malignancy. Irritative symptoms will present alone in ˜30% of cases, usually with invasive cancer or CIS. Other less common presentations include flank pain (ureteral obstruction), pelvic pain (spread outside bladder), and leg edema (lymphatic involvement). A secondary urinary tract infection may be present in up to 30% of patients.
a urologic malignancy. Irritative symptoms will present alone in ˜30% of cases, usually with invasive cancer or CIS. Other less common presentations include flank pain (ureteral obstruction), pelvic pain (spread outside bladder), and leg edema (lymphatic involvement). A secondary urinary tract infection may be present in up to 30% of patients.
▪ Physical Examination
The physical examination is usually unremarkable except in far advanced disease. A bimanual examination should be performed at the time of cystoscopy. A palpable tumor indicates that at least the muscular wall is involved.
▪ Laboratory Tests
Urinalysis and culture are performed to confirm hematuria and to look for evidence of infection. Even if infection is demonstrated and hematuria clears after treatment with antibiotics, further investigation should be undertaken in high-risk individuals (age, sex, industrial exposure, and smoker).
▪ Imaging
A computed tomography (CT) scan of the abdomen and pelvis with intravenous contrast should be obtained in all patients with hematuria, preferably before cystoscopy in case retrograde studies are needed to further delineate filling defects in the upper tracts. A negative bladder on CT does not exclude a bladder tumor and therefore does not cancel the need for cystoscopy. Ureteral obstruction or bladder displacement suggests an invasive tumor. In patients with iodine contrast sensitivity, bilateral retrograde pyelograms can be performed at the time of cystoscopy if indicated. Few patients with bladder tumors will have concurrent upper tract lesions; however, one-third of patients with upper tract tumors will have an associated bladder cancer.